|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Chee CE and Sinicrope FA: Targeted
therapeutic agents for colorectal cancer. Gastroenterol Clin North
Am. 39:601–613. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keen N and Taylor S: Aurora-kinase
inhibitors as anticancer agents. Nat Rev Cancer. 4:927–936. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang KT, Li SK, Chang CC, et al: Aurora-C
kinase deficiency causes cytokinesis failure in meiosis I and
production of large polyploid oocytes in mice. Mol Biol Cell.
21:2371–2383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bischoff JR, Anderson L, Zhu Y, et al: A
homologue of Drosophila Aurora kinase is oncogenic and amplified in
human colorectal cancers. EMBO J. 17:3052–3065. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pohl A, Azuma M, Zhang W, et al:
Pharmacogenetic profiling of Aurora kinase B is associated with
overall survival in metastatic colorectal cancer. Pharmacogenomics
J. 11:93–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ilyas M, Straub J, Tomlinson IP and Bodmer
WF: Genetic pathways in colorectal and other cancers. Eur J Cancer.
35:1986–2002. 1999. View Article : Google Scholar
|
|
9
|
Senda T, Iizuka-Kogo A, Onouchi T and
Shimomura A: Adenomatous polyposis coli (APC) plays multiple roles
in the intestinal and colorectal epithelia. Med Mol Morphol.
40:68–81. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanson CA and Miller JR: Non-traditional
roles for the Adenomatous Polyposis Coli (APC) tumor suppressor
protein. Gene. 361:1–12. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boman BM, Walters R, Fields JZ, et al:
Colonic crypt changes during adenoma development in familial
adenomatous polyposis: immunohistochemical evidence for expansion
of the crypt base cell population. Am J Pathol. 165:1489–1498.
2004. View Article : Google Scholar
|
|
12
|
Zhang T, Fields JZ, Opdenaker L, et al:
Survivin-induced Aurora-B kinase activation: A mechanism by which
APC mutations contribute to increased mitoses during colon cancer
development. Am J Pathol. 177:2816–2826. 2010. View Article : Google Scholar
|
|
13
|
Wilkinson RW, Odedra R, Heaton SP, et al:
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human
tumor xenograft growth by inducing apoptosis. Clin Cancer Res.
13:3682–3688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Preston S, Leedham S, Oukrif D, et al: The
development of duodenal microadenomas in FAP patients: the human
correlate of the Min mouse. J Pathol. 214:294–301. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Minde DP, Anvarian Z, Rüdiger SG and
Maurice MM: Messing up disorder: how do missense mutations in the
tumor suppressor protein APC lead to cancer? Mol Cancer.
10:1012011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen LC, Hao CY, Chiu YS, et al:
Alteration of gene expression in normal-appearing colon mucosa of
APC(min) mice and human cancer patients. Cancer Res. 64:3694–3700.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Corpet DE and Pierre F: How good are
rodent models of carcinogenesis in predicting efficacy in humans? A
systematic review and meta-analysis of colon chemoprevention in
rats, mice and men. Eur J Cancer. 41:1911–1922. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mortlock AA, Foote KM, Heron NM, et al:
Discovery, synthesis, and in vivo activity of a new class of
pyrazoloquinazolines as selective inhibitors of aurora B kinase. J
Med Chem. 50:2213–2224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cummings J, Hodgkinson C, Odedra R, et al:
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug
induced tumor cell death and antitumor activity. Mol Cancer Ther.
7:455–463. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wedge SR, Ogilvie DJ, Dukes M, et al:
ZD4190: an orally active inhibitor of vascular endothelial growth
factor signaling with broad-spectrum antitumor efficacy. Cancer
Res. 60:970–975. 2000.
|
|
21
|
Widrow RJ, Rabinovitch PS, Cho K and Laird
CD: Separation of cells at different times within G2 and mitosis by
cyclin B1 flow cytometry. Cytometry. 27:250–254. 1997. View Article : Google Scholar
|
|
22
|
Alferez D, Ryan A, Goodlad R, Wright N and
Wilkinson R: Effects of vandetanib on adenoma formation in a
dextran sodium sulphate enhanced ApcMIN/+ mouse model.
Int J Oncol. 37:767–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alferez D, Wilkinson RW, Watkins J, et al:
Dual inhibition of VEGFR and EGFR signaling reduces the incidence
and size of intestinal adenomas in Apc(Min/+) mice. Mol Cancer
Ther. 7:590–598. 2008.PubMed/NCBI
|
|
24
|
Goodlad RA, Ryan AJ, Wedge SR, et al:
Inhibiting vascular endothelial growth factor receptor-2 signaling
reduces tumor burden in the ApcMin/+ mouse model of early
intestinal cancer. Carcinogenesis. 27:2133–2139. 2006.PubMed/NCBI
|
|
25
|
Alferez D and Goodlad R: To best measure
cell proliferation in samples from the intestine. Cell Prolif.
40:231–240. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nair JS, Ho AL, Tse AN, et al: Aurora B
kinase regulates the postmitotic endoreduplication checkpoint via
phosphorylation of the retinoblastoma protein at serine 780. Mol
Biol Cell. 20:2218–2228. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ditchfield C, Johnson VL, Tighe A, et al:
Aurora B couples chromosome alignment with anaphase by targeting
BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol. 161:267–280.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ota T, Suto S, Katayama H, et al:
Increased mitotic phosphorylation of histone H3 attributable to
AIM-1/Aurora-B overexpression contributes to chromosome number
instability. Cancer Res. 62:5168–5177. 2002.PubMed/NCBI
|
|
29
|
Lens SM, Voest EE and Medema RH: Shared
and separate functions of polo-like kinases and aurora kinases in
cancer. Nat Rev Cancer. 10:825–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oke A, Pearce D, Wilkinson RW, et al:
AZD1152 rapidly and negatively affects the growth and survival of
human acute myeloid leukemia cells in vitro and in vivo. Cancer
Res. 69:4150–4158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aihara A, Tanaka S, Yasen M, et al: The
selective Aurora B kinase inhibitor AZD1152 as a novel treatment
for hepatocellular carcinoma. J Hepatol. 52:63–71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nair JS, de Stanchina E and Schwartz GK:
The topoisomerase I poison CPT-11 enhances the effect of the aurora
B kinase inhibitor AZD1152 both in vitro and in vivo. Clin Cancer
Res. 15:2022–2030. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Azzariti A, Bocci G, Porcelli L, et al:
Aurora B kinase inhibitor AZD1152: determinants of action and
ability to enhance chemotherapeutics effectiveness in pancreatic
and colon cancer. Br J Cancer. 104:769–780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grundy M, Seedhouse C, Russell NH and
Pallis M: P-glycoprotein and breast cancer resistance protein in
acute myeloid leukaemia cells treated with the aurora-B kinase
inhibitor barasertib-hQPA. BMC Cancer. 11:2542011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tentler JJ, Bradshaw-Pierce EL, Serkova
NJ, et al: Assessment of the in vivo antitumor effects of
ENMD-2076, a novel multi-targeted kinase inhibitor, against primary
and cell line-derived human colorectal cancer xenograft models.
Clin Cancer Res. 16:2989–2998. 2010. View Article : Google Scholar
|
|
36
|
Girdler F, Gascoigne KE, Eyers PA, et al:
Validating Aurora B as an anti-cancer drug target. J Cell Sci.
119:3664–3675. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boivin GP, Washington K, Yang K, et al:
Pathology of mouse models of intestinal cancer: consensus report
and recommendations. Gastroenterology. 124:762–777. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Paulsen JE: Modulation by dietary factors
in murine FAP models. Toxicol Lett. 112–113:403–409.
2000.PubMed/NCBI
|
|
39
|
Rhodes JM and Campbell BJ: Inflammation
and colorectal cancer: IBD-associated and sporadic cancer compared.
Trends Mol Med. 8:10–16. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alison M: The Cancer Handbook. John Wiley
& Sons, Chichester; West Sussex, Hoboken, NJ: 2007
|
|
41
|
Boss DS, Witteveen PO, van der Sar J, et
al: Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B
kinase, in patients with solid malignant tumors. Ann Oncol.
22:431–437. 2011. View Article : Google Scholar : PubMed/NCBI
|
